Premium
AMAG Pharmaceuticals Inc (AMAG)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal...
Covis Group Completes Acquisition of AMAG Pharmaceuticals PR Newswire LUXEMBOURG and ZUG, Switzerland, Nov. 16, 2020 LUXEMBOURG and ZUG, Switzerland, Nov. 16, 2020 /PRNewswire/ -- Covis Group S.à...
Covis Group Completes Acquisition of AMAG Pharmaceuticals PR Newswire LUXEMBOURG and ZUG, Switzerland, Nov. 16, 2020 LUXEMBOURG and ZUG, Switzerland, Nov. 16, 2020 /PRNewswire/ -- Covis Group S.à...
MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600 PR Newswire NEW YORK, Nov. 5, 2020 NEW YORK...
Covis Group S.à r.l. Announces Commencement of Tender Offer for All Outstanding Shares of AMAG Pharmaceuticals, Inc. PR Newswire LUXEMBOURG and ZUG, Switzerland, Oct. 15, 2020 LUXEMBOURG and ZUG...
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug...
The product remains on the marketAMAG has 15 days to respond to the FDAAMAG continues to expect its recently announced tender offer and merger to close in November 2020 WALTHAM, Mass., Oct. 05...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of AMAG Pharmaceuticals, Inc. PR Newswire NEW YORK, Oct. 2, 2020 NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rowley Law PLLC is...
Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses Covis will commence...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
